Recently, Viva Biotech's portfolio companies have new updates: Arthrosi entered into a major acquisition agreement and had previously completed its Series E financing, Proviva also successfully completed financing; Ophidion and AmacaThera entered into a major collaboration; Domain and Basking made solid progress in R&D.
01 M&A and Financing
· Arthrosi Enters into an Acquisition Agreement with Sobi for a Total Transaction Value of up to US$1.5 Billion, following the Completion of $153 Million in Series E Financing
Stockholm, Sweden — Dec. 13, 2025, Swedish Orphan Biovitrum AB (STO:SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which was invested in and incubated by Viva Biotech Holdings. Under the terms of the agreement, Sobi will pay up to US$1.5 billion in total transaction value, including an upfront payment at closing of US$950 million, subject to customary adjustments, and contingent consideration of up to US$550 million. The transaction is expected to close in the first half of 2026.
On Oct. 8, Arthrosi announced the closing of its $153 million Series E financing and the company plans to use the proceeds to complete the clinical development of its lead program, pozdeutinurad (AR882), through its replicate Phase 3 REDUCE 1 and REDUCE 2 studies evaluating pozdeutinurad for the treatment of gout and tophaceous gout.
· Proviva Therapeutics Raises Over $30 Million in Series A+ Financing to Advance First-in-Class PD-1/IL-2 Pro-drug Fusion Protein PTX-912
Dec. 1, 2025 — Proviva Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), announced the successful completion of its over $30 million Series A+ financing. The round was led by OrbiMed, with participation from renowned investors including Hankang Capital, HSG and a well-known global fund. Proceeds will support the global clinical development of the company’s lead asset, PTX-912, and advance multiple additional preclinical programs.
02 Key Collaborations
· Ophidion, Inc. and Neuronasal, Inc. Announce Strategic Collaborations to Tackle Parkinson's Disease, Obesity, and Diabetes via Novel CNS Delivery Platform
PASADENA, Calif. — Dec. 15, 2025, Ophidion, Inc., invested and incubated by Viva BioInnovator (VBI), a biotechnology company pioneering non-invasive delivery of gene-silencing and large-molecule therapeutics to the brain, and Neuronasal, Inc., a clinical-stage company advancing patented nose-to-brain delivery of therapeutics, announced a strategic partnership to co-develop multiple therapeutic candidates targeting key pathways in Parkinson's disease as well as the treatment of obesity and diabetes.
· AmacaThera Signs Exclusive Global Licensing Agreement with Pacira BioSciences for Up To US$230 Million, Validating Its Tunable Drug Delivery Platform
TORONTO — Nov. 4, 2025, AmacaThera, invested and incubated by Viva BioInnovator (VBI), a leading developer of next generation hydrogel-based drug delivery solutions that enable precise, tunable, and sustained release to improve a wide range of active therapeutics, announced an exclusive worldwide licensing agreement with Pacira BioSciences, Inc., a leader in non-opioid pain management, for the development and commercialization of AMT-143, an investigational long-acting non-opioid anesthetic for post-operative pain.
Under the terms of the agreement, AmacaThera will receive US$5 million upfront and up to US$225 million in future development- and sales-based milestone payments and a tiered royalty on future net sales. The companies will collaborate on clinical development, with AmacaThera leading select clinical studies. Pacira will fund clinical development of AMT-143 through commercial launch.
03 R&D Updates
· Domain Therapeutics Doses First Patients in Phase I / II Trial of DT-7012 Targeting CCR8 in Solid Tumors
Strasbourg, France – Montreal, Canada – Boston, United States, Oct. 28, 2025: Domain Therapeutics, invested and incubated by Viva BioInnovator (VBI), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for patients, announced that the first patients have been dosed in its Phase I / II DOMISOL clinical study of DT-7012, a differentiated Treg-depleting anti-CCR8 monoclonal antibody for the treatment of solid tumors.
· Basking Biosciences Doses First Patients in Part B of Phase 2 Stroke Trial, Unlocks $27.5 Million Financing Tranche
RESEARCH TRIANGLE, N.C. — Oct. 22, 2025, Basking Biosciences (Basking), invested and incubated by Viva BioInnovator (VBI), a clinical-stage biopharmaceutical company developing the first reversible thrombolytic therapy for acute ischemic stroke (AIS), announced the first patients dosed in Part B of its Phase 2 RAISE trial of BB-031.
Progression into Part B, supported by encouraging early results from Part A and the recommendation of the Data Safety Monitoring Committee (DSMC), triggered the release of the second $27.5 million tranche of the company's $55 million financing. The new funds will support the execution of Part B of the Phase 2 RAISE trial and a planned Phase 1 study of BB-025.
About Arthrosi
Arthrosi Therapeutics, Inc., headquartered in San Diego, CA, is focused on developing pozdeutinurad, a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate levels, flares and tophi in patients with progressive gout. The rights to pozdeutinurad in Greater China are held by ApicHope.
About Proviva Therapeutics
Founded in 2019, Proviva Therapeutics is a clinical-stage biotechnology company pioneering the development of novel immuno-cytokine therapeutics for cancer. Leveraging its proprietary CROSSOVER pro-drug platform and MUSICA multifunctional effector cell activation technology, Proviva is building a globally competitive pipeline targeting major unmet needs in cancer treatment. The company’s lead program, PTX-912, a first-in-class PD-1-proIL-2 fusion protein, has already demonstrated excellent tolerability profile and promising anti-tumor activity in early stage clinical testing.
About Ophidion, Inc.
Ophidion is an early-stage CNS biopharmaceutical company developing non-invasive therapeutics for neurodegenerative disorders. Its proprietary carrier technology is designed to deliver large molecules and oligonucleotides into the brain via intravenous administration. The company is advancing programs in Huntington's disease, Alzheimer's disease, and Parkinson's disease. (ophidion.com)
About AmacaThera
AmacaThera is a leading developer of next-generation hydrogel-based drug delivery solutions. Transforming from liquid to gel at body temperature, AmacaThera's hydrogel enables drugs to be delivered to and stay precisely where they are needed and released over days or weeks, depending on the specific needs of each therapeutic application. Building on this foundation, AmacaThera leverages its proprietary hydrogel platform to co-develop innovative drug delivery solutions with pharmaceutical and biotechnology partners. For more information, please visit: www.amacathera.com
About Domain Therapeutics
Domain Therapeutics is a clinical-stage biopharmaceutical company developing highly differentiated therapeutic strategies targeting G protein-coupled receptors (GPCRs), a crucial class of drug targets. Its robust regulatory and clinical pipeline aims to address significant unmet medical needs, offering novel solutions for patients, particularly in immuno-oncology and inflammation. Domain's key programs include a best-in-class Treg-depleting anti-CCR8 antibody and a first-in-class biased antagonist of PAR2. These innovative therapies are driving value creation, positioning the company in competitive and fast-expanding markets.
About Basking Biosciences
Basking Biosciences is a clinical-stage biopharmaceutical company dedicated to changing the way potentially life-threatening blood clots are treated. Its novel therapies are designed to significantly improve safety and efficacy, broadening access to many more patients. The company's lead candidate, BB-031, is the first rapid-onset, short-acting thrombolytic therapy with a reversal agent, currently in development for the treatment of acute ischemic stroke. By inhibiting von Willebrand Factor (vWF), a key driver in clot formation, BB-031 offers targeted, potent thrombolytic activity that, together with its reversal agent, could enable more patients to receive timely, life-saving treatment after stroke. For more information, visit www.baskingbiosciences.com.
